Insider trade

10% owner sold ~$8.03M of LLY shares in the open market

Traded Nov 17, 2025 · Filed Nov 18, 2025

Eli LillyLLY

~$8.03M
Reported value · 7,789 sh @ $1,030.448: 92.9M
Holds after · shares reported: +12.5%
stock since the trade · S&P 500 +14.8%, $1,021.70 → $1,149.85 on Oct 1

Why it stands out

A big owner of Eli Lilly sold $8.03M of Eli Lilly shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 17, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 18, 2025

10% owner$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$8,026,159

Shares × reported transaction price

Timing vs results

18 days after results of Oct 30, 2025, 79 days before results of Feb 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $1,021.70 on Nov 17, 2025, within 1% of its 52-week high, after a 21% rise over the previous 30 trading days

52-week range $625.65 (Aug 8, 2025) to $1,025.28 (Nov 14, 2025), 99% of the way up, from 250 adjusted closes. 30 trading days earlier: $845.05 on Oct 6, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Retevmo on Nov 20, 2025, 3 days after this trade.

New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+5.2%	+2.6%	+2.6%
30 days	+2.1%	+2.7%	-0.6%
90 days	-1.3%	+3.0%	-4.3%
180 days	-5.9%	+11.5%	-17.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0000316011-25-000075
Filed / recorded: Nov 18, 2025, 9:00 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: ELI LILLY & Co
Issuer CIK: 59478
Ticker: LLY
Reporting person: LILLY ENDOWMENT INC
Relationship: 10% owner
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 17, 2025
Transaction code: S
Shares / units: 7,789
Price per share: $1,030.448
Acquired / disposed: Disposed (D)
Shares owned after: 92,874,288
Ownership form: Direct
Amendment: No

Footnotes from the filing

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) and (2) to this Form 4.

Around the same time

10mo ago

4.67Shares · @ $1,062.19

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

10mo ago

13.97Shares · @ $1,062.19

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

10mo ago

9.34Shares · @ $1,062.19

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record